Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citalopram for reflux hypersensitivity and functional heartburn
2024-517019-57-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastroesophageal reflux disease (GERD), reflux hypersensitivity (RH) and Functional heartburn (FH) comparing Citalopram with Placebo (2 arms). Primary endpoint: Change in number of reflux episodes. Planned start Oct 2024; status: authorised.
02
Drugs
citalopram
03
Conditions
gastroesophageal reflux disease (GERD)reflux hypersensitivity (RH)Functional heartburn (FH)
Beyond the preview
Go deeper on 2024-517019-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517019-57-00.